The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

Mads Ammitzbøll-Danielsen; Mikkel Østergaard; Esperanza Naredo; Annamaria Iagnocco; Ingrid Möller; Maria Antonietta D'Agostino; Frédérique Gandjbakhch; Lene Terslev

doi:10.3899/jrheum.170501

The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

Mads Ammitzbøll-Danielsen^*, Mikkel Østergaard, Esperanza Naredo, Annamaria Iagnocco, Ingrid Möller, Maria Antonietta D'Agostino, Frédérique Gandjbakhch, Lene Terslev

^*Corresponding author for this work

Department of Clinical Medicine

3 Citations (Scopus)

Abstract

Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

Original language	English
Journal	Journal of Rheumatology
Volume	45
Issue number	2
Pages (from-to)	165-169
ISSN	0315-162X
DOIs	https://doi.org/10.3899/jrheum.170501
Publication status	Published - 2018

Keywords

Omeract
Rheumatoid arthritis
Tenosynovitis
Ultrasonography

Access to Document

10.3899/jrheum.170501

Cite this

@article{77871381b65a4cf0b8a6088d0930ef0b,

title = "The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials",

abstract = "Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.",

keywords = "Omeract, Rheumatoid arthritis, Tenosynovitis, Ultrasonography",

author = "Mads Ammitzb{\o}ll-Danielsen and Mikkel {\O}stergaard and Esperanza Naredo and Annamaria Iagnocco and Ingrid M{\"o}ller and D'Agostino, {Maria Antonietta} and Fr{\'e}d{\'e}rique Gandjbakhch and Lene Terslev",

year = "2018",

doi = "10.3899/jrheum.170501",

language = "English",

volume = "45",

pages = "165--169",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology Publishing Co. Ltd.",

number = "2",

}

TY - JOUR

T1 - The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

AU - Ammitzbøll-Danielsen, Mads

AU - Østergaard, Mikkel

AU - Naredo, Esperanza

AU - Iagnocco, Annamaria

AU - Möller, Ingrid

AU - D'Agostino, Maria Antonietta

AU - Gandjbakhch, Frédérique

AU - Terslev, Lene

PY - 2018

Y1 - 2018

N2 - Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

AB - Objective: To test the sensitivity to change of the Outcome Measures in Rheumatology Clinical Trials (OMERACT) ultrasound (US) scoring system for tenosynovitis when applied in a multicenter design. Methods: RA patients with US-verified tenosynovitis were recruited when scheduled for treatment intensification. Tenosynovitis was assessed at baseline, and 3 and 6 months followup, using the semiquantitative OMERACT scoring system. Results: Expressed in median (25th; 75th percentiles), the overall greyscale and Doppler score decreased significantly from baseline at 4 (2; 7) and 3 (2; 6), to 6 months at 2 (0; 3) and 0 (0; 1, p < 0.01), respectively, and showed high responsiveness (standardized response mean = 0.8). Conclusion: The OMERACT US scoring system for tenosynovitis showed high responsiveness, supporting its use for diagnosing and monitoring tenosynovitis in multicenter trials.

KW - Omeract

KW - Rheumatoid arthritis

KW - Tenosynovitis

KW - Ultrasonography

U2 - 10.3899/jrheum.170501

DO - 10.3899/jrheum.170501

M3 - Journal article

C2 - 29247153

AN - SCOPUS:85041654986

SN - 0315-162X

VL - 45

SP - 165

EP - 169

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 2

ER -

The use of the OMERACT ultrasound tenosynovitis scoring system in multicenter clinical trials

Abstract

Keywords

Access to Document

Fingerprint

Cite this